Dupixent and vaccines bring Sanofi back to growth by Angus Liu Wednesday, October 31, 2018 Dupixent grew sales by 28% sequentially at constant currencies, to €225 million, and that doesn't even count a recent major approval in asthma.
Pentaxim hold in China trips up Sanofi's vaccine momentum by Eric Sagonowsky Tuesday, May 1, 2018 Sanofi posted strong vaccines growth last year, but the first quarter of 2018 didn't deliver quite so well.
